Sandoz Group Ltd Sponsored ADR AI Stock Analysis
Want to see SDZNY full AI Analyst Report?
Sandoz Group Ltd Sponsored ADR (SDZNY) AI Stock Analysis
Sandoz Group Ltd Sponsored ADR
(Other OTC:SDZNY)
Improving financial performance and strong earnings-call momentum support the score, reinforced by favorable technical trends. The main constraint is expensive valuation, while overbought technical readings and pricing, legal, and CapEx pressures add risk.
Sandoz Group Ltd Sponsored ADR (SDZNY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $41.80B
- Dividend Yield
- 1.06%
- Average Volume (3M)
- 20.55K
- Price to Earnings (P/E)
- 64.9
- Beta (1Y)
- 0.71
- Revenue Growth
- 9.56%
- EPS Growth
- 180.05%
- Country
- US
- Employees
- 23,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Sandoz Group Ltd Sponsored ADR Business Overview & Revenue Model
Company Description
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharma...
Sandoz Group Ltd Sponsored ADR Earnings Call Summary
The call presented a broadly positive performance story: strong biosimilar-led top-line growth, margin expansion, resilient cash generation despite a significant CapEx cycle, an enlarged 36-asset biosimilar pipeline, major product launches with leading market shares, and strategic investments (Ljubljana center) that support medium-term growth. Near-term challenges include increased pricing erosion (now expected mid-single-digit), temporary generics headwinds (notably in Q1 and in some international markets), short-term tender/pricing disruption in Germany, elevated one-off and settlement-related cash outflows, and a heavier CapEx profile in 2026. Management reaffirmed 2026 guidance and emphasized confidence in 2027–2028 growth driven by upcoming launches and the multisource GLP-1 strategy. On balance, the positives around revenue momentum, profitability improvement, pipeline breadth, and strong commercial execution outweigh the near-term operational and pricing headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management confirmed 2026 guidance: net sales are expected to increase mid‑ to high‑single‑digit at constant currencies (H1 sales were USD 5.8bn, +5% cc), core EBITDA margin is targeted to expand by around 100 basis points (H1 margin 20.9%, +90bps Y/Y), and overall pricing is now expected to decline by a mid‑single‑digit percentage in 2026 (revised from a prior low‑to‑mid‑single‑digit view). They now assume a ~2 percentage‑point FX tailwind to net sales for the year (previously ~4pp) and still do not expect material FX impact on the core EBITDA margin; CapEx is expected to peak this cycle at ~USD 1.1bn (H1 CapEx ≈ USD 500m) while management free cash flow remained around USD 500m in H1, one‑off costs are expected at ~USD 0.3bn for the year, and the balance sheet targets include net debt/EBITDA below 2x (net debt ≈ USD 3.5bn, net‑debt-to-core‑EBITDA 1.4x, gross debt USD 5.9bn, liquidity USD 2.3bn, average borrowing cost <4%).
Sandoz Group Ltd Sponsored ADR Financial Statement Overview
Summary
Stable gross margins, improving 2025 profitability, stronger cash flow, and manageable leverage support the score. Revenue softness, historical cash-flow volatility, and ROE below 10% remain limitations.
Income Statement
72PositiveBalance Sheet
68PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.62B | 11.15B | 10.38B | 11.66B | 9.30B | 9.62B |
| Gross Profit | 5.52B | 5.24B | 4.93B | 5.33B | 4.38B | 4.54B |
| EBITDA | 2.48B | 2.26B | 742.00M | 1.00B | 1.73B | 1.87B |
| Net Income | 645.84M | 919.12M | 1.00M | 89.99M | 847.75M | 907.82M |
Balance Sheet | ||||||
| Total Assets | 22.79B | 22.03B | 19.91B | 22.71B | 17.55B | 17.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.25B | 1.74B | 1.19B | 1.30B | 80.01M | 39.86M |
| Total Debt | 6.20B | 5.68B | 4.85B | 5.32B | 4.18B | 4.93B |
| Total Liabilities | 13.79B | 12.65B | 11.74B | 12.59B | 8.80B | 9.35B |
| Stockholders Equity | 9.00B | 9.38B | 8.16B | 10.10B | 83.41K | 8.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.22B | 810.00M | 60.00M | -307.36M | 821.99M | 935.82M |
| Operating Cash Flow | 1.72B | 1.59B | 656.00M | 423.06M | 1.22B | 1.35B |
| Investing Cash Flow | -2.06B | -980.00M | -740.00M | -717.57M | -464.93M | -690.87M |
| Financing Cash Flow | 159.95M | -197.00M | 242.00M | 1.45B | -831.47M | -656.87M |
Sandoz Group Ltd Sponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDZNY, the sentiment is Positive. The current price of 96.67 is below the 20-day moving average (MA) of 100.21, above the 50-day MA of 91.44, and above the 200-day MA of 85.43, indicating a neutral trend. The MACD of 2.29 indicates Positive momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 2.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SDZNY.
Sandoz Group Ltd Sponsored ADR Peers Comparison
Overall Rating
KNSA80Outperform
CORT76Outperform
SDZNY71Outperform
LQDA60Neutral
SCYX53Neutral
BFRI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $7.47B | 66.47 | 17.27% | ― | 58.19% | 192.34% | |
| 76Outperform | $7.42B | 45.19 | 22.94% | ― | 30.02% | 48.80% | |
| 71Outperform | $43.31B | 64.90 | 7.04% | 1.06% | 9.56% | 180.05% | |
| 60Neutral | $5.08B | -54.76 | -116.64% | ― | 798.44% | 27.88% | |
| 53Neutral | $28.07M | -2.41 | -18.65% | ― | 543.96% | 72.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 38Underperform | $10.65M | -1.50 | -110.30% | ― | 29.85% | 78.56% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SDZNY | Sandoz Group Ltd Sponsored ADR | 96.67 | 31.02 | 47.26% | |
| CORT | Corcept Therapeutics | 67.79 | -7.26 | -9.67% | |
| SCYX | SCYNEXIS Inc | 2.82 | -2.70 | -48.91% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 95.05 | 53.56 | 129.09% | |
| LQDA | Liquidia Technologies | 56.40 | 27.84 | 97.48% | |
| BFRI | Biofrontera, Inc. | 0.60 | -0.15 | -20.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
